IS8339A - Mótlyf viðtaka NOGO - Google Patents
Mótlyf viðtaka NOGOInfo
- Publication number
- IS8339A IS8339A IS8339A IS8339A IS8339A IS 8339 A IS8339 A IS 8339A IS 8339 A IS8339 A IS 8339A IS 8339 A IS8339 A IS 8339A IS 8339 A IS8339 A IS 8339A
- Authority
- IS
- Iceland
- Prior art keywords
- nogo receptor
- nogo
- receptor antagonists
- antigen
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2003/025004 WO2004014311A2 (en) | 2002-08-10 | 2003-08-07 | Nogo receptor antagonists |
PCT/US2004/002702 WO2005016955A2 (en) | 2003-08-07 | 2004-01-30 | Nogo receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IS8339A true IS8339A (is) | 2006-03-07 |
Family
ID=34192565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS8339A IS8339A (is) | 2003-08-07 | 2006-03-07 | Mótlyf viðtaka NOGO |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1660517A4 (ja) |
JP (1) | JP2007501612A (ja) |
CN (1) | CN1926147A (ja) |
AU (1) | AU2004264405A1 (ja) |
BR (1) | BRPI0413426A (ja) |
CA (1) | CA2535007A1 (ja) |
IS (1) | IS8339A (ja) |
MX (1) | MXPA06001444A (ja) |
NO (1) | NO20061081L (ja) |
PL (1) | PL380274A1 (ja) |
WO (1) | WO2005016955A2 (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7119165B2 (en) | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
ATE469913T1 (de) | 2002-08-10 | 2010-06-15 | Univ Yale | Antagonisten des nogo-rezeptors |
ES2215470B1 (es) | 2002-09-30 | 2005-12-16 | Bsh Electrodomesticos España, S.A. | Aparato de aire acondicionado. |
ES2215469B1 (es) | 2002-09-30 | 2005-12-16 | Bsh Electrodomesticos España, S.A. | Aparato de aire acondicionado. |
PL1606409T3 (pl) | 2003-03-19 | 2011-02-28 | Biogen Ma Inc | Białko wiążące receptor Nogo |
JP4960865B2 (ja) | 2004-06-24 | 2012-06-27 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 脱髄に関連する状態の処置 |
EP1789070B1 (en) | 2004-08-03 | 2012-10-24 | Biogen Idec MA Inc. | Taj in neuronal function |
WO2006124627A2 (en) * | 2005-05-12 | 2006-11-23 | Biogen Idec Ma Inc. | Methods of treating conditions involving neuronal degeneration |
US7893032B2 (en) | 2005-07-07 | 2011-02-22 | Yale University | NgR variants and compositions thereof for suppressing axonal growth inhibition |
SI1904104T1 (sl) | 2005-07-08 | 2013-12-31 | Biogen Idec Ma Inc. | Protitelesa SP35 in njihova uporaba |
JP2009510002A (ja) | 2005-09-30 | 2009-03-12 | アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 反発誘導分子(rgm)タンパク質ファミリーのタンパク質の結合ドメイン、及びその機能的断片、及びそれらの使用 |
US8669345B2 (en) | 2006-01-27 | 2014-03-11 | Biogen Idec Ma Inc. | Nogo receptor antagonists |
WO2008013782A2 (en) | 2006-07-24 | 2008-01-31 | Biogen Idec Ma Inc. | Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists |
US20080119820A1 (en) | 2006-09-20 | 2008-05-22 | Phan Phillip C | Methods for Delivering Volatile Anesthetics for Regional Anesthesia and/or Pain Relief |
ES2609924T3 (es) * | 2006-11-21 | 2017-04-25 | Abbott Laboratories | Anticuerpos monoclonales neutralizantes contra el receptor de Nogo-66 (NGR) y usos de los mismos |
JP5789100B2 (ja) | 2008-01-22 | 2015-10-07 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 抽出溶媒を含む、局部的な麻酔および/または疼痛低減のための揮発性麻酔薬組成物 |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
CA2729961C (en) | 2008-07-09 | 2018-05-01 | Biogen Idec Ma Inc. | Li113, li62 variant co2, anti-lingo antibodies |
JP5951498B2 (ja) | 2009-12-08 | 2016-07-13 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | 網膜神経線維層変性の治療に使用するためのrgmaタンパク質に対するモノクローナル抗体 |
NZ625403A (en) | 2012-01-27 | 2016-03-31 | Abbvie Inc | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
MX2014013950A (es) | 2012-05-14 | 2015-02-17 | Biogen Idec Inc | Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras. |
CA2973266A1 (en) | 2015-01-08 | 2016-07-14 | Biogen Ma Inc. | Lingo-1 antagonists and uses for treatment of demyelinating disorders |
CN110488007A (zh) * | 2019-09-26 | 2019-11-22 | 天津华科泰生物技术有限公司 | 一种快速检测神经胶质纤维酸性蛋白的免疫层析检测卡及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999066041A1 (en) * | 1998-06-16 | 1999-12-23 | Human Genome Sciences, Inc. | 94 human secreted proteins |
WO2003035687A1 (en) * | 2001-10-22 | 2003-05-01 | Novartis Ag | Nogo receptor homologues and their use |
-
2004
- 2004-01-30 JP JP2006522535A patent/JP2007501612A/ja active Pending
- 2004-01-30 BR BRPI0413426-5A patent/BRPI0413426A/pt not_active IP Right Cessation
- 2004-01-30 CA CA002535007A patent/CA2535007A1/en not_active Abandoned
- 2004-01-30 CN CNA2004800294122A patent/CN1926147A/zh active Pending
- 2004-01-30 EP EP04707073A patent/EP1660517A4/en not_active Withdrawn
- 2004-01-30 AU AU2004264405A patent/AU2004264405A1/en not_active Abandoned
- 2004-01-30 PL PL380274A patent/PL380274A1/pl not_active Application Discontinuation
- 2004-01-30 WO PCT/US2004/002702 patent/WO2005016955A2/en active Application Filing
- 2004-01-30 MX MXPA06001444A patent/MXPA06001444A/es unknown
-
2006
- 2006-03-06 NO NO20061081A patent/NO20061081L/no not_active Application Discontinuation
- 2006-03-07 IS IS8339A patent/IS8339A/is unknown
Also Published As
Publication number | Publication date |
---|---|
CA2535007A1 (en) | 2005-02-24 |
PL380274A1 (pl) | 2007-01-22 |
JP2007501612A (ja) | 2007-02-01 |
NO20061081L (no) | 2006-04-18 |
BRPI0413426A (pt) | 2006-10-17 |
WO2005016955A2 (en) | 2005-02-24 |
CN1926147A (zh) | 2007-03-07 |
MXPA06001444A (es) | 2006-05-15 |
AU2004264405A1 (en) | 2005-02-24 |
EP1660517A4 (en) | 2006-10-04 |
EP1660517A2 (en) | 2006-05-31 |
WO2005016955A3 (en) | 2006-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS8339A (is) | Mótlyf viðtaka NOGO | |
NO20050685L (no) | NOGO-reseptorantagonister | |
WO2007089601A3 (en) | Nogo receptor antagonists | |
CY1116863T1 (el) | Πρωτεϊνη δεσμευσης υποδοχεα nogo | |
DE60329489D1 (de) | Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon | |
EA200600376A1 (ru) | Антагонисты nogo-рецептора |